UCM Technologies Inc. Presented a Revolutionary Three-Biomarker Signature Test for Early Stage (Stages I-II) Detection of Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2023 Meeting in Chicago IL
CHICAGO, IL / ACCESSWIRE / June 4, 2023 / UCM Technologies has utilized a breakthrough combination of biomarkers (CA-62, CEA and CYFRA 21-1) to detect...